Skip to main content
Erschienen in: Virchows Archiv 3/2006

01.03.2006 | Original Article

Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement

verfasst von: Raphael Schiffmann, Amy Rapkiewicz, Mones Abu-Asab, Markus Ries, Hasan Askari, Maria Tsokos, Martha Quezado

Erschienen in: Virchows Archiv | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

We describe the postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant α-galactosidase A for more than 2 years. The patient had widespread atherosclerotic coronary artery disease that culminated in a massive acute myocardial infarction. Atherosclerotic lesions were seen in the right and left coronary systems, aorta, and the basilar artery. Typical Fabry cardiomyopathy and glomerular nephropathy were found. With the exception of vascular endothelial cells, extensive glycolipid storage deposits were seen in all vascular and nonvascular cells and organ systems. We conclude that, at least in this patient, repeated infusions with α-galactosidase A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells. These findings also illustrate accelerated atherosclerosis in susceptible patients with Fabry disease.
Literatur
1.
Zurück zum Zitat (1984) Case 2-1984: Fabry’s disease. N Engl J Med 310:1607 (1984) Case 2-1984: Fabry’s disease. N Engl J Med 310:1607
2.
Zurück zum Zitat Altarescu G, Moore DF, Schiffmann R (2005) Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 64:2148–2150PubMedCrossRef Altarescu G, Moore DF, Schiffmann R (2005) Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 64:2148–2150PubMedCrossRef
3.
Zurück zum Zitat Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA, Eitzman DT (2005) Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111:629–632CrossRefPubMed Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA, Eitzman DT (2005) Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111:629–632CrossRefPubMed
4.
Zurück zum Zitat Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167PubMedCrossRef Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167PubMedCrossRef
5.
Zurück zum Zitat Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774 Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774
6.
Zurück zum Zitat Duncan C, McLeod GM (1970) Angiokeratoma corporis diffusum universale (Fabry’s disease): a case with gross myocardial involvement. Australas Ann Med 19:58–61PubMed Duncan C, McLeod GM (1970) Angiokeratoma corporis diffusum universale (Fabry’s disease): a case with gross myocardial involvement. Australas Ann Med 19:58–61PubMed
7.
Zurück zum Zitat Elleder M (2003) Sequelae of storage in Fabry disease—pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl 92:46–53; discussion 45CrossRefPubMed Elleder M (2003) Sequelae of storage in Fabry disease—pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl 92:46–53; discussion 45CrossRefPubMed
8.
Zurück zum Zitat Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry’s disease. N Engl J Med 345:9–16CrossRefPubMed Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry’s disease. N Engl J Med 345:9–16CrossRefPubMed
9.
Zurück zum Zitat Fisher EA, Desnick RJ, Gordon RE, Eng CM, Griepp R, Goldman ME (1992) Fabry disease: an unusual cause of severe coronary disease in a young man. Ann Intern Med 117:221–223PubMed Fisher EA, Desnick RJ, Gordon RE, Eng CM, Griepp R, Goldman ME (1992) Fabry disease: an unusual cause of severe coronary disease in a young man. Ann Intern Med 117:221–223PubMed
10.
Zurück zum Zitat Gadoth N, Sandbank U (1983) Involvement of dorsal root ganglia in Fabry’s disease. J Med Genet 20:309–312PubMedCrossRef Gadoth N, Sandbank U (1983) Involvement of dorsal root ganglia in Fabry’s disease. J Med Genet 20:309–312PubMedCrossRef
11.
Zurück zum Zitat Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra C, Miebach E, Beck M (2002) Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 91:21–27CrossRefPubMed Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra C, Miebach E, Beck M (2002) Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 91:21–27CrossRefPubMed
12.
Zurück zum Zitat Kotnik J, Kotnik F, Desnick RJ (2005) Fabry disease. A case report. Acta Dermatovenerolog Alp Panon Adriat 14:15–19 Kotnik J, Kotnik F, Desnick RJ (2005) Fabry disease. A case report. Acta Dermatovenerolog Alp Panon Adriat 14:15–19
13.
Zurück zum Zitat Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J, Elleder M, Aschermann M (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24:75–83; discussion 65CrossRefPubMed Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J, Elleder M, Aschermann M (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24:75–83; discussion 65CrossRefPubMed
14.
Zurück zum Zitat Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506–1512PubMedCrossRef Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506–1512PubMedCrossRef
15.
Zurück zum Zitat Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, Steiner RD, Rhead WJ, Brady RO, Hazen SL, Schiffmann R (2004) Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality—an arterial spin tagging study. J Magn Reson Imaging 20:674–683CrossRefPubMed Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, Steiner RD, Rhead WJ, Brady RO, Hazen SL, Schiffmann R (2004) Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality—an arterial spin tagging study. J Magn Reson Imaging 20:674–683CrossRefPubMed
16.
Zurück zum Zitat Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 33:164–168CrossRefPubMed Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 33:164–168CrossRefPubMed
17.
Zurück zum Zitat Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703–710CrossRefPubMed Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703–710CrossRefPubMed
18.
Zurück zum Zitat Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 285:2743–2749CrossRefPubMed Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 285:2743–2749CrossRefPubMed
19.
Zurück zum Zitat Senechal M, Germain DP (2003) Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 63:46–52CrossRefPubMed Senechal M, Germain DP (2003) Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 63:46–52CrossRefPubMed
20.
Zurück zum Zitat Tabira T, Goto I, Kuroiwa Y, Kikuchi M (1974) Neuropathological and biochemical studies in Fabry’s disease. Acta Neuropathol 30:345–354CrossRefPubMed Tabira T, Goto I, Kuroiwa Y, Kikuchi M (1974) Neuropathological and biochemical studies in Fabry’s disease. Acta Neuropathol 30:345–354CrossRefPubMed
21.
Zurück zum Zitat Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O’Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933–1946CrossRefPubMed Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O’Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933–1946CrossRefPubMed
22.
Zurück zum Zitat Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74CrossRefPubMed Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74CrossRefPubMed
Metadaten
Titel
Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement
verfasst von
Raphael Schiffmann
Amy Rapkiewicz
Mones Abu-Asab
Markus Ries
Hasan Askari
Maria Tsokos
Martha Quezado
Publikationsdatum
01.03.2006
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 3/2006
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-005-0089-x

Weitere Artikel der Ausgabe 3/2006

Virchows Archiv 3/2006 Zur Ausgabe

Announcements

Announcements

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …